#USA #San Diego #Class Action #Robbins LLP #Unicycive Therapeutics

Unicycive Therapeutics Faces Class Action Lawsuit

Unicycive Therapeutics, Inc., a clinical-stage biotech firm focused on therapies for kidney diseases, is currently embroiled in a class action lawsuit. This legal action has been initiated by Robbins LLP on behalf of investors who held Unicycive’s securities from December 29, 2025, to June 29, 2026. The lawsuit stems from allegations that the company did not sufficiently scrutinize its third-party manufacturing vendor’s facility, directly impacting its compliance with U.S. Food and Drug Administration (FDA) standards.

Allegations of Compliance Deficiencies

According to court documents, Unicycive submitted a New Drug Application (NDA) for its kidney disease treatment known as oxylanthanum carbonate (OLC) in September 2024, which was subsequently accepted by the FDA in November of the same year. However, the FDA raised red flags in June 2025 when they issued a Complete Response Letter (CRL), citing problems with a third-party manufacturer that needed resolution before moving forward. Unicycive's subsequent communications with the FDA highlighted concerns involving the vendor’s adherence to good manufacturing practices.

During the complaint period, it is asserted that the company failed to disclose essential information, including:
1. The lack of an inspection of the third-party manufacturer’s facility.
2. The absence of a solid basis to assume that identified deficiencies were rectified.
3. Undisclosed risks concerning the potential need for further information by the FDA about manufacturing practices.
4. Insights suggesting a delay in obtaining regulatory approval for OLC.
5. Misleading statements about the company's operational stability and future prospects.

Market Reaction and Stock Performance

On June 30, 2026, Unicycive publicly revealed that the FDA reiterated its concerns in yet another CRL regarding the company’s resubmitted NDA for OLC, reiterating the same manufacturing issues initially pointed out in the June 2025 letter. Following this disclosure, the company's stock price plummeted by $3.01, equating to a staggering 39.1% drop, closing at $4.69 per share. This fall was exacerbated by an unusual surge in trading volume, signaling strong investor reaction to the negative news.

Investors’ Legal Rights

The ongoing lawsuit aims to represent all investors who acquired Unicycive Therapeutics’ securities within the specified time frame. Those affected by financial losses during this period may have legal options under federal securities laws. The lead plaintiff in a class action is a court-appointed individual who embodies the interests of all class members through the litigation process. Importantly, one does not have to fulfill the role of lead plaintiff to benefit from any potential recovery resulting from the case’s outcome.

Unicycive shareholders wishing to take a more aggressive approach may contact Robbins LLP prior to the lead plaintiff deadline on November 2, 2026.

Cost of Participation

Investors should note that participation in this legal action does not incur any costs upfront; Robbins LLP operates on a contingency fee basis. This means that they only receive payment if the case is won, making it a viable option for investors looking to seek partial restitution of their losses.

About Robbins LLP

Robbins LLP is recognized as a prominent leader in litigation involving shareholders' rights, holding a strong track record in securities fraud cases. The firm has successfully restored over $1 billion in value to shareholders and has achieved remarkable recoveries in derivative actions. According to Brian J. Robbins, the firm’s founding partner, “Companies have an obligation to provide investors with complete and accurate information so that markets can function fairly and efficiently.”

Investors wishing to stay informed about any developments concerning Unicycive Therapeutics, including settlements or updates regarding corporate executive conduct, can register for the Stock Watch service through Robbins LLP.

Conclusion

As this case unfolds, all eyes will be on how Unicycive Therapeutics navigates this crisis and the implications for those who have invested in their promising yet now troubled enterprise. Investors suffering from significant losses in this timeframe are encouraged to explore their legal options promptly.